Summary: Poland has built a reputation as a major European tech hub, driving high demand for artificial intelligence and machine learning talent across cities such as Warsaw, Kraków and Wrocław. Global companies including Lenovo, GitLab and Zendesk are actively expanding their local teams. Poland has emerged as one of Central Europe's most dynamic tech hubs
Amkor Technology (AMKR) vs Recursion Pharmaceuticals Inc (RXRX): Price, Performance & Key Differences | Pluang
Price performance (Past 24H)
Key statistics
Key statistics
Amkor Technology vs Recursion Pharmaceuticals Inc — how do they compare? Amkor Technology trades at $51.73 (market cap $12.85B), while Recursion Pharmaceuticals Inc trades at $3.2 (market cap $1.73B). The key difference: Amkor Technology is far larger — about 7.4× Recursion Pharmaceuticals Inc’s market cap, and Amkor Technology pays a 0.65% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMKR | RXRX | |
|---|---|---|
|
Market Cap |
$12.85B | $1.73B |
|
Sector |
Technology | Health |
|
52-Week High |
$93.55 | $6.79 |
|
52-Week Low |
$25.46 | $2.84 |
|
Enterprise Value |
$12.93B | $1.25B |
|
Dividend Yield |
0.65% | — |
Aura AI Summary
Signals from Pluang’s Aura AI — not financial advice
Aura AI Summary
Signals from Pluang’s Aura AI — not financial advice
Amkor Technology
AMKR trades at $51.73, up 0.74% today, with a neutral technical stance. The stock shows strong earnings beats in recent quarters and a 50% analyst buy rating. Recent news highlights a $12 billion Arizona expansion for advanced packaging, backed by partnerships with TSMC and NVIDIA, signaling long-term growth potential amid near-term volatility.
Outlook is positive due to robust earnings momentum and strategic investments, but risks include high capital expenditures and semiconductor cycle sensitivity. The consensus price target of $77 suggests significant upside, supported by institutional accumulation and AI-driven demand tailwinds.
Recursion Pharmaceuticals Inc
RXRX trades at $3.20, down 0.47% with a bearish technical outlook. The clinical-stage biotech shows deep losses with -961.97% net margin but beat earnings estimates in 2 of 3 recent quarters. Cash flow remains negative from operations, offset by financing activities. Analyst sentiment is mixed with 40% buy ratings amid pipeline expansion in AI-driven drug discovery.
The stock faces significant execution risk with negative profitability, though partnerships with Roche and pipeline progress offer long-term potential. High cash burn requires continued financing, making near-term performance dependent on clinical milestones and partnership revenues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amkor Technology
Amkor Technology provides outsourced semiconductor packaging and test services. It helps chipmakers assemble, protect, and test semiconductors for computing, communications, automotive, and consumer applications.
Read more on AMKR →
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company’s unique approach combines one of the world’s largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
More comparisons
Related Posts
